Skip to main content

WIN Consortium to Use Foundation Medicine Test in 200-Patient Trial Starting 2013

Premium

The Worldwide Innovative Networking Consortium in personalized cancer medicine plans to use Foundation Medicine's cancer genome profiling test in an upcoming clinical trial, the company said last week.

A company spokesperson told Clinical Sequencing News that the trial will involve 200 patients, who will be enrolled starting in early 2013. Each patient will be evaluated with the firm's sequencing-based test, FoundationOne, and be matched to a targeted therapy where possible.

The test "will allow physicians participating in this trial to test for alterations in clinically relevant genes known to be associated with human cancer and match these alterations with appropriate targeted therapies or clinical trials," said John Mendelsohn, chairman of the WIN Consortium, in a statement.

The WIN Consortium, which Foundation Medicine joined in March, is an international network of 22 academic institutions and companies. It was started by the Cancer Institute Gustave Roussy in France and the University of Texas MD Anderson Cancer Center and focuses on international biomarker-driven therapeutic clinical trials.

Foundation Medicine launched its test in May and said recently that it plans to conduct several clinical trials to show the test's efficacy and its impact on doctors' decisions (CSN 6/13/2012).

The test sequences 3,230 exons of 182 genes known to be mutated in solid tumors, as well as 37 introns from 14 genes known to be rearranged in these cancers.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.